CD109 Plays a Role in Osteoclastogenesis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wang, Yongqiang ^a   Inger, Maayan ^a   Jiang, Hongwei ^a   Tenenbaum, Howard ^a   Glogauer, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN CD109; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUSION; CONTROLLED STUDY; MACROPHAGE; MICROARRAY ANALYSIS; MONOCYTE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; CELL FUSION; CELL LINE; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOCLASTS; OSTEOGENESIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

MURINAE;

EID: 84876078606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061213     Document Type: Article

References (55)

1. Asagiri M, Takayanagi H, (2007) The molecular understanding of osteoclast differentiation. Bone 40: 251-264.
2. Roodman GD, (1999) Cell biology of the osteoclast. Exp Hematol 27: 1229-1241.
3. Miyamoto T, Suda T, (2003) Differentiation and function of osteoclasts. Keio J Med 52: 1-7.
4. Vaananen HK, Zhao H, Mulari M, Halleen JM, (2000) The cell biology of osteoclast function. J Cell Sci 113 (Pt 3): 377-381.
5. Leung R, Wang Y, Cuddy K, Sun C, Magalhaes J, et al. Filamin A regulates monocyte migration through Rho small GTPases during osteoclastogenesis. J Bone Miner Res 25: 1077-1091.
6. Cochran DL, (2008) Inflammation and bone loss in periodontal disease. J Periodontol 79: 1569-1576.
7. Yasuda H, (1998) [Osteoclastogenesis inhibitory factor (OCIF)]. Seikagaku 70: 385-390.
8. Kim MH, Park M, Baek SH, Kim HJ, Kim SH, Molecules and signaling pathways involved in the expression of OC-STAMP during osteoclastogenesis. Amino Acids 40: 1447-1459.
9. Anderson PH, Sawyer RK, Moore AJ, May BK, O'Loughlin PD, et al. (2008) Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res 23: 1789-1797.
10. Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA, (2006) RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38: 678-685.
11. Troen BR, (2003) Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 38: 605-614.
12. Yen ML, Hsu PN, Liao HJ, Lee BH, Tsai HF, TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation. PLoS One 7: e38048.
13. Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, et al. (2002) Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99: 1683-1691.
14. Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, et al. CD109 expression levels in malignant melanoma. J Dermatol Sci 57: 140-142.
15. Smith JW, Hayward CP, Horsewood P, Warkentin TE, Denomme GA, et al. (1995) Characterization and localization of the Gova/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets. Blood 86: 2807-2814.
16. Kelton JG, Smith JW, Horsewood P, Warner MN, Warkentin TE, et al. (1998) ABH antigens on human platelets: expression on the glycosyl phosphatidylinositol-anchored protein CD109. J Lab Clin Med 132: 142-148.
17. Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, et al. (1999) CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 27: 1282-1294.
18. Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, et al. The TGF-beta co-receptor, CD109, promotes internalization and degradation of TGF-beta receptors. Biochim Biophys Acta 1813: 742-753.
19. Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, et al. CD109-mediated degradation of TGF-beta receptors and inhibition of TGF-beta responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem 113: 238-246.
20. Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, et al. (2006) Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB J 20: 1525-1527.
21. Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, et al. (2008) Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 99: 1916-1923.
22. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
23. Hasegawa M, Hagiwara S, Sato T, Jijiwa M, Murakumo Y, et al. (2007) CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int 57: 245-250.
24. Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, et al. (2008) CD109 expression in basal-like breast carcinoma. Pathol Int 58: 288-294.
25. Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, et al. (2007) High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 57: 719-724.
26. Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, et al. (2005) CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 55: 165-169.
27. Man XY, Finnson KW, Baron M, Philip A, CD109, a TGF-beta co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther 14: R144.
28. Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, et al. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int 60: 735-743.
29. Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, et al. CD109 release from the cell surface in human keratinocytes regulates TGF-beta receptor expression, TGF-beta signalling and STAT3 activation: relevance to psoriasis. Exp Dermatol 20: 627-632.
30. Ballanti P, Minisola S, Pacitti MT, Scarnecchia L, Rosso R, et al. (1997) Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry. Osteoporos Int 7: 39-43.
31. Gradin P, Hollberg K, Cassady A I, Lang P, Andersson G, Transgenic overexpression of tartrate-resistant Acid phosphatase is associated with induction of osteoblast gene expression and increased cortical bone mineral content and density. Cells Tissues Organs 196: 68-81.
32. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
33. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3Article3.
34. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
35. Porto-Diaz I, Bolon-Canedo V, Alonso-Betanzos A, Fontenla-Romero O, A study of performance on microarray data sets for a classifier based on information theoretic learning. Neural Netw 24: 888-896.
36. Maskos U, Southern EM, (1992) Oligonucleotide hybridizations on glass supports: a novel linker for oligonucleotide synthesis and hybridization properties of oligonucleotides synthesised in situ. Nucleic Acids Res 20: 1679-1684.
37. Schena M, Shalon D, Davis RW, Brown PO, (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470.
38. Lashkari DA, DeRisi JL, McCusker JH, Namath AF, Gentile C, et al. (1997) Yeast microarrays for genome wide parallel genetic and gene expression analysis. Proc Natl Acad Sci U S A 94: 13057-13062.
39. Yavropoulou MP, Yovos JG, (2008) Osteoclastogenesis--current knowledge and future perspectives. J Musculoskelet Neuronal Interact 8: 204-216.
40. Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, et al. (2004) Expression of CD109 in human cancer. Oncogene 23: 3716-3720.
41. Nakamura I, Rodan GA, Duong le T, (2003) Regulatory mechanism of osteoclast activation. J Electron Microsc (Tokyo) 52: 527-533.
42. Lee G, Santat LA, Chang MS, Choi S, (2009) RNAi methodologies for the functional study of signaling molecules. PLoS One 4: e4559.
43. Yang G, Zaidi M, Zhang W, Zhu LL, Li J, et al. (2008) Functional grouping of osteoclast genes revealed through microarray analysis. Biochem Biophys Res Commun 366: 352-359.
44. Yang M, Birnbaum MJ, MacKay CA, Mason-Savas A, Thompson B, et al. (2008) Osteoclast stimulatory transmembrane protein (OC-STAMP), a novel protein induced by RANKL that promotes osteoclast differentiation. J Cell Physiol 215: 497-505.
45. Nolan T, Hands RE, Bustin SA, (2006) Quantification of mRNA using real-time RT-PCR. Nat Protoc 1: 1559-1582.
46. Morey JS, Ryan JC, Van Dolah FM, (2006) Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol Proced Online 8: 175-193.
47. Jenson SD, Robetorye RS, Bohling SD, Schumacher JA, Morgan JW, et al. (2003) Validation of cDNA microarray gene expression data obtained from linearly amplified RNA. Mol Pathol 56: 307-312.
48. Chen J, Sun Y, Mao X, Liu Q, Wu H, et al. RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis. J Biol Chem 285: 36315-36321.
49. Tam BY, Finnson KW, Philip A, (2003) Glycosylphosphatidylinositol-anchored proteins regulate transforming growth factor-beta signaling in human keratinocytes. J Biol Chem 278: 49610-49617.
50. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, et al. (2001) Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 16: 1787-1794.
51. Koseki T, Gao Y, Okahashi N, Murase Y, Tsujisawa T, et al. (2002) Role of TGF-beta family in osteoclastogenesis induced by RANKL. Cell Signal 14: 31-36.
52. Yan T, Riggs BL, Boyle WJ, Khosla S, (2001) Regulation of osteoclastogenesis and RANK expression by TGF-beta1. J Cell Biochem 83: 320-325.
53. Fox SW, Lovibond AC, (2005) Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol 243: 19-26.
54. Mitchell H, Choudhury A, Pagano RE, Leof EB, (2004) Ligand-dependent and-independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11. Mol Biol Cell 15: 4166-4178.
55. Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, et al. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res 26: 1447-1456.